Clinical Trial Update: Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating adjuvant modified FOLFIRINOX for high-risk stage III colon cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Modified FOLFIRINOX (modified FOLFIRINOX)

Snippet

Sponsor: Chungnam National University Hospital | Conditions: Colon Cancer Stage III | Phase 2, Phase 3 | Status: RECRUITING